Trail­ing ri­vals, As­traZeneca of­fers a hit and a miss on key car­dio study for SGLT2 di­a­betes drug Farx­i­ga

As­traZeneca had some good news for its in­vestors ear­ly Mon­day morn­ing, re­port­ing that their Phase III car­dio study of­fered some com­pelling proof of their SGLT2 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER